Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study
Open Access
- 15 July 2003
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 4 (3) , 255-262
- https://doi.org/10.1046/j.1468-1293.2003.00156.x
Abstract
Objectives To describe the prevalence and risk factors of poor CD4 count rise despite a good virological response on highly active antiretroviral treatment (HAART). Methods The patients from the EuroSIDA study who started HAART with a baseline CD4 count of <350 cells/μL and where all viral load (pVL) measures remained below 500 HIV‐1 RNA copies/mL between 6 and 12 months after the start of HAART were included. The risk factors for poor CD4 count rise were analyzed by multiple regression. Results Seven hundred and eighty patients were included. A low CD4 count response was observed in 225 patients (29%). The risk factors for this condition were older age, lower CD4 count at baseline, higher increase from the nadir to baseline CD4 count and lower pVL at baseline. Patients taking ≥one drug from each of the three antiviral classes were more likely to have a good CD4 response but a minority of the study participants was taking this treatment regimen (3.1%) and the confidence interval was large. Conclusions A poor immune reconstitution despite a good virological control is frequent after initiation of HAART among patients with a baseline CD4 count of <350 cells/μL. The underlying mechanisms leading to this condition seems mainly driven by the age and the baseline immunological and virological status of the patients.Keywords
This publication has 20 references indexed in Scilit:
- Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapyAIDS, 2002
- Predictors of Long‐Term Increase in CD4+Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral RegimenThe Journal of Infectious Diseases, 2002
- Possible mechanism of toxicity of zidovudine by induction of apoptosis of CD4+ and CD8+ T-cells in vivo.European Journal of Clinical Microbiology & Infectious Diseases, 2001
- Long‐Term Clinical Outcome of Human Immunodeficiency Virus–Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor–Containing RegimenThe Journal of Infectious Diseases, 2001
- Rapid Effect of Interleukin?2 Therapy in Human Immunodeficiency Virus–Infected Patients whose CD4 Cell Counts Increase Only Slightly in Response to Combined Antiretroviral TreatmentThe Journal of Infectious Diseases, 2001
- Clinical and Immunological Benefits from Highly Active Antiretroviral Therapy in Spite of Limited Viral Load Reduction in HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2001
- Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNAAIDS, 2000
- Dissociation of Immunologic and Virologic Responses to Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virus—Infected Patients Receiving Antiretroviral TherapyClinical Infectious Diseases, 2000
- Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapyAIDS, 1999